Chronic Kidney Disease Elevates Risk of Vascular Calcification

Conference|American Society of Nephrology (ASN) Kidney Week

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses how chronic kidney disease elevated the risk of vascular calcification and what the risks of vascular calcification are.

In a Pharmacy Times® interview, Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, about his ASN 2021 Kidney Week presentation on the prevention of vascular calcification in chronic kidney disease.

He discussed how chronic kidney disease elevated the risk of vascular calcification and what the risks of vascular calcification are.

Related Videos
Credit: Lars Neumann - stock.adobe.com
Image Credit: Adobe Stock - peterschreiber.media
Conference attendees watching a speaker | Image credit: kasto - stock.adobe.com
Biosimilars | Image credit: lexiconimages - stock.adobe.com
Medical care team | Image credit: Iryna - stock.adobe.com
Pharmacist helping patient | Image credit: Zamrznuti tonovi - stock.adobe.com
Pharmacist in home infusion environment | Image credit: Satjawat - stock.adobe.com
Medical science laboratory | Image credit: alphaspirit - stock.adobe.com
Gastroenterologist using digital x-ray of human intestine holographic scan projection 3D rendering | Image Credit: sdecoret - stock.adobe.com
Related Content

Long-term Data Show Efficacy of Amivantamab-vmjw Combination for Patients With Mutated Advanced Non-Small Cell Lung Cancer

June 5th 2023

Pharmacy Focus: Independent Rx Forum- What to Know for the NCPA 2022 Annual Convention

June 23rd 2022

Durvalumab, Olaparib Combination Improves Progression-Free Survival in Patients With Advanced Ovarian Cancer

June 5th 2023

Pharmacy Focus: On The Shelf - Camille Schrier, 2019 and 2020 Miss America

May 31st 2022

Overall Survival Results Reinforce Osimertinib is Now Standard of Care for EGFRm Stage IB–IIIA NSCLC

June 5th 2023

With Perioperative Pembrolizumab, Event-Free Survival for Early-Stage Lung Cancer Was 62% at the Interim Analysis of Phase 3 KEYNOTE-671

June 4th 2023

Long-term Data Show Efficacy of Amivantamab-vmjw Combination for Patients With Mutated Advanced Non-Small Cell Lung Cancer

June 5th 2023

Pharmacy Focus: Independent Rx Forum- What to Know for the NCPA 2022 Annual Convention

June 23rd 2022

Durvalumab, Olaparib Combination Improves Progression-Free Survival in Patients With Advanced Ovarian Cancer

June 5th 2023

Pharmacy Focus: On The Shelf - Camille Schrier, 2019 and 2020 Miss America

May 31st 2022

Overall Survival Results Reinforce Osimertinib is Now Standard of Care for EGFRm Stage IB–IIIA NSCLC

June 5th 2023

With Perioperative Pembrolizumab, Event-Free Survival for Early-Stage Lung Cancer Was 62% at the Interim Analysis of Phase 3 KEYNOTE-671

June 4th 2023

Long-term Data Show Efficacy of Amivantamab-vmjw Combination for Patients With Mutated Advanced Non-Small Cell Lung Cancer

June 5th 2023

Pharmacy Focus: Independent Rx Forum- What to Know for the NCPA 2022 Annual Convention

June 23rd 2022

Durvalumab, Olaparib Combination Improves Progression-Free Survival in Patients With Advanced Ovarian Cancer

June 5th 2023

Pharmacy Focus: On The Shelf - Camille Schrier, 2019 and 2020 Miss America

May 31st 2022

Overall Survival Results Reinforce Osimertinib is Now Standard of Care for EGFRm Stage IB–IIIA NSCLC

June 5th 2023

With Perioperative Pembrolizumab, Event-Free Survival for Early-Stage Lung Cancer Was 62% at the Interim Analysis of Phase 3 KEYNOTE-671

June 4th 2023
© 2023 MJH Life Sciences

All rights reserved.